Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasma cell | 10 studies | 40% ± 13% | |
fibroblast | 10 studies | 30% ± 10% | |
plasmablast | 5 studies | 40% ± 18% | |
pancreatic A cell | 4 studies | 27% ± 9% | |
type B pancreatic cell | 4 studies | 39% ± 14% | |
connective tissue cell | 4 studies | 29% ± 13% | |
IgG plasma cell | 4 studies | 23% ± 5% | |
astrocyte | 4 studies | 40% ± 20% | |
epithelial cell | 4 studies | 39% ± 13% | |
goblet cell | 4 studies | 21% ± 5% | |
IgA plasma cell | 3 studies | 28% ± 5% | |
basal cell | 3 studies | 30% ± 2% | |
mesothelial cell | 3 studies | 36% ± 13% | |
ciliated cell | 3 studies | 22% ± 4% | |
Mueller cell | 3 studies | 19% ± 2% | |
plasmacytoid dendritic cell | 3 studies | 18% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 9023.15 | 328 / 328 | 100% | 235.46 | 178 / 178 |
prostate | 100% | 7859.37 | 245 / 245 | 99% | 211.16 | 498 / 502 |
ovary | 100% | 15705.60 | 180 / 180 | 99% | 176.43 | 426 / 430 |
stomach | 100% | 3780.71 | 359 / 359 | 99% | 181.78 | 282 / 286 |
adrenal gland | 100% | 5212.51 | 258 / 258 | 98% | 301.92 | 226 / 230 |
esophagus | 99% | 3025.21 | 1424 / 1445 | 99% | 224.48 | 182 / 183 |
skin | 99% | 5035.34 | 1790 / 1809 | 99% | 243.56 | 466 / 472 |
thymus | 100% | 7310.84 | 653 / 653 | 97% | 154.11 | 588 / 605 |
intestine | 98% | 2631.56 | 943 / 966 | 99% | 182.23 | 522 / 527 |
lung | 99% | 5704.14 | 575 / 578 | 97% | 166.62 | 1121 / 1155 |
bladder | 100% | 4449.95 | 21 / 21 | 96% | 158.24 | 485 / 504 |
kidney | 100% | 4572.78 | 89 / 89 | 96% | 143.23 | 865 / 901 |
brain | 96% | 3764.56 | 2528 / 2642 | 100% | 151.67 | 704 / 705 |
breast | 96% | 2963.13 | 439 / 459 | 97% | 153.58 | 1090 / 1118 |
uterus | 100% | 6079.23 | 170 / 170 | 92% | 140.94 | 421 / 459 |
liver | 100% | 6436.45 | 225 / 226 | 90% | 95.69 | 367 / 406 |
eye | 0% | 0 | 0 / 0 | 100% | 259.04 | 80 / 80 |
ureter | 0% | 0 | 0 / 0 | 100% | 52.06 | 1 / 1 |
blood vessel | 100% | 10142.37 | 1330 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 11049.87 | 851 / 861 | 0% | 0 | 0 / 0 |
adipose | 92% | 2837.15 | 1106 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 95.22 | 41 / 45 |
spleen | 81% | 1845.11 | 196 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 69% | 38.36 | 20 / 29 |
muscle | 41% | 790.13 | 328 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 17% | 412.91 | 158 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030206 | Biological process | chondroitin sulfate biosynthetic process |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005829 | Cellular component | cytosol |
GO_0032580 | Cellular component | Golgi cisterna membrane |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0050510 | Molecular function | N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0047238 | Molecular function | glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity |
Gene name | CHPF |
Protein name | Hexosyltransferase (EC 2.4.1.-) Chondroitin sulfate synthase 2 (EC 2.4.1.175) (EC 2.4.1.226) (Chondroitin glucuronyltransferase 2) (Chondroitin-polymerizing factor) (ChPF) (Glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase II) (N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase II) (N-acetylgalactosaminyltransferase 2) |
Synonyms | UNQ651/PRO1281 CSS2 |
Description | FUNCTION: Has both beta-1,3-glucuronic acid and beta-1,4-N-acetylgalactosamine transferase activity. Transfers glucuronic acid (GlcUA) from UDP-GlcUA and N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of the elongating chondroitin polymer. Seems to act as a specific activating factor for CHSY1 in chondroitin polymerization . .; FUNCTION: [Isoform 2]: May facilitate PRKN transport into the mitochondria. In collaboration with PRKN, may enhance cell viability and protect cells from oxidative stress. . |
Accessions | Q8IZ52 ENST00000691864.1 ENST00000535926.3 [Q8IZ52-4] ENST00000688634.1 ENST00000243776.11 [Q8IZ52-1] F8W6H2 A0A8I5QJC8 ENST00000373891.3 |